Table of Contents
Chapter 1. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Executive Summary
1.1. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size & Forecast (2024-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Type
1.3.2. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Dynamics
3.1. Market Drivers
3.1.1. Increasing prevalence of cancer and demand for early diagnosis
3.1.2. Technological advancements in liquid biopsy and CTC detection
3.1.3. Growing focus on personalized medicine and targeted therapies
3.2. Market Challenges
3.2.1. High cost of advanced CTC prognostic technologies
3.2.2. Regulatory hurdles and complexity in clinical adoption
3.3. Market Opportunities
3.3.1. Expansion in emerging markets
3.3.2. Integration of AI and machine learning in CTC technologies
3.3.3. Increasing research collaborations and partnerships
Chapter 4. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size & Forecasts by Type 2024-2032
5.1. Segment Dashboard
5.2. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. Tumor Cell Enrichment
5.2.2. Tumor Cell Detection
Chapter 6. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size & Forecasts by Application 2024-2032
6.1. Segment Dashboard
6.2. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Prostate Cancer
6.2.2. Breast Cancer
6.2.3. Colorectal Cancer
6.2.4. Lung Cancer
6.2.5. Ovarian Cancer
6.2.6. Pancreatic Cancer
Chapter 7. Global Circulating Tumor Cells (CTCs) Prognostic Technologies Market Size & Forecasts by Region 2024-2032
7.1. North America Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.1.1. U.S. Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.1.1.1. Type breakdown size & forecasts, 2024-2032
7.1.1.2. Application breakdown size & forecasts, 2024-2032
7.1.2. Canada Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.1.2.1. Type breakdown size & forecasts, 2024-2032
7.1.2.2. Application breakdown size & forecasts, 2024-2032
7.2. Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.2.1. UK Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.2.2. Germany Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.2.3. France Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.2.4. Spain Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.2.5. Italy Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.2.6. Rest of Europe Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3. Asia-Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3.1. China Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3.1.1. Type breakdown size & forecasts, 2024-2032
7.3.1.2. Application breakdown size & forecasts, 2024-2032
7.3.2. India Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3.2.1. Type breakdown size & forecasts, 2024-2032
7.3.2.2. Application breakdown size & forecasts, 2024-2032
7.3.3. Japan Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3.4. Australia Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3.5. South Korea Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.3.6. Rest of Asia Pacific Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.4. Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.4.1. Brazil Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.4.2. Mexico Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.4.3. Rest of Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.5. Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.5.1. Saudi Arabia Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.5.2. South Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market
7.5.3. Rest of Middle East & Africa Circulating Tumor Cells (CTCs) Prognostic Technologies Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Menarini Silicon Biosystems
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. QIAGEN N.V.
8.3.3. Bio-Techne Corporation
8.3.4. Biocept, Inc.
8.3.5. ApoCell, Inc.
8.3.6. Fluxion Biosciences, Inc.
8.3.7. Greiner Bio-One GmbH
8.3.8. Epic Sciences
8.3.9. Ikonisys Inc.
8.3.10. Advanced Cell Diagnostics (ACD)
8.3.11. Guardant Health
8.3.12. CellSearch (Johnson & Johnson)
8.3.13. Cynvenio Biosystems, Inc.
8.3.14. ScreenCell
8.3.15. Foundation Medicine, Inc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes